

STATEMENT SHOWING PRILIMINARY TECHNICAL EVALUATION FOR T NO 168-2 (GENERAL MEDICINES)					
S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
1	BHARAT BIOTECH INTERNATIONAL LIMITED	Technical Evaluation Remarks by DGDCA: The firm may be considered			
		140224091	Recombinant Human Epidermal Growth Factor 150 Nanogram/gram Gel		May be considered
		140224090	Recombinant Human Epidermal Growth Factor 60 Nanogram/gram Gel		May be considered
2	CIPLA LTD	Technical Evaluation Remarks by DGDCA: The firm may not be considered as they produced documents of Loan Licenses only			
		140224038	Cap.Levosalbutamol respule 0.63mg/3ml	Produced loan license	May not be considered
		1976	Warfarin sodium Tablets IP 3 mg	Produced loan license	May not be considered
3	Eurokem Laboratories Pvt Ltd.	Technical Evaluation Remarks by DGDCA: The firm may be considered only after submission of the following documents (1) Valid GMP certificate, stating whether the firm has complied GMP or not (2) Valid NCC for whole firm instead of for certain products			
		1319	Pantaprazole (Enteric Coated) Tablets 40mg		May be considered
4	Glenmark Pharmaceuticals Ltd	Technical Evaluation Remarks by DGDCA: The firm may be considered after obtaining clarification from APMSIDC/DME			

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status	
		2290	Flucinolone Acetonide 0.01 Percentage w/w Lotion 30 ml		May be considered	
		23012410	Glycopirronium 50mcg	The bidder has submitted product license for Glycopirrodine powder for inhalation in capsule form whereas the tender document did not contain required formulation. Hence clarification required from APMSIDC/DME May be considered after getting clarification from APMSIDC/DME	NA	
5	Imaging Products India Pvt Ltd	<p>Technical Evaluation Remarks by DGDCA: The firm may be considered only after submission of the following queries (1) Valid Form-10 import license for S.No. 2 (2) Valid GMP/WHO-GMP/COPP for items S.No. 1 & S.No. 4 (3) Product licenses for S.No. 1 & S.No. 4</p> <p>Firm may be considered after submission of Annexure-II (Original Declaration form), Annexure-V (Mfg Capacity and Batch size as per tender format)</p>				
	1	1900	Non Ionic Contrast Media (Iohexol) 400/50 (50ml)	Not produced valid import license	May not be considered	
	2	140224109	Non-ionic contrast-gadotridol 0.5M 10ml/15ml	pg no 29 Form-10 valid upto 12/09/24, Not submitted renewed Form-10	May not be considered	
	3	140224104	Non-ionic contrast-Iomeprol 400mg 50ml/100ml	pg no 25 Form-10 no.633 valid for 06/12/25	May be considered	
	4	140224106	Oral contrast-Sodium diatrizoate 25 percentage 30ml/100ml	Not produced valid product license	May not be considered	

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status	
6	M/s Sparsha Pharma International Private Limited	<p>Technical Evaluation Remarks by DGDCA: The description for the above drugs is not complete, The tender document should have mentioned below (1) For Nicotine Patch 7mg : Each 10cm2 Nicotine patch contains 17.5mg nicotine which delivers Nicotine @7mg/24hrs (2) For Nicotine Patch 14mg : Each 20cm2 Nicotine patch contains 35mg nicotine which delivers Nicotine @14mg/24hrs (3) For Nicotine Patch 21mg : Each 30cm2 Nicotine patch contains 52.5mg nicotine which delivers Nicotine @21mg/24hrs</p> <p>Hence necessary corrections may be made/clarification required from DME/Concerned Department in order to consider the above products</p>				
		4004	Nicotine Patch 14 mg	Product license specifications did not match with required strength May be considered after getting clarification from bidder	May not be considered	
		4003	Nicotine Patch 21 mg	Product license specifications did not match with required strength May be considered after getting clarification from bidder	May not be considered	
		4005	Nicotine Patch 7 mg	Product license specifications did not match with required strength May be considered after getting clarification from bidder	May not be considered	
7	Rathnam pharmaceuticals pvt ltd	<p>Technical Evaluation Remarks by DGDCA: The firm may be considered after receiving (1) Valid GMP (2) Valid Form 25 license (3) Valid NCC (4) Valid Product approval</p> <p>Firm may be considered after submission of Annexure-II (Affidavit), Annexure-III (detailed quoted products), Annexure-IV(CA certificate) and Annexure-V (Mfg Capacity and Batch size as per tender format)</p>				
		1319	Pantaprazole (Enteric Coated) Tablets 40mg	Not submitted product approval	May not be considered	
8	Roche Products India Pvt Ltd	<p>Technical Evaluation Remarks by DGDCA: The firm may be considered</p>				
		140224111	Emizicumab 105mg/0.7ml		May be considered	

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
9	RUSAN PHARMA LIMITED	Technical Evaluation Remarks by DGDCA: The description for the above drugs is not complete, The tender document should have mentioned the following details (1) For Nicotine Patch 7mg : Each 10cm2 Nicotine patch contains 17.5mg nicotine which delivers Nicotine @7mg/24hrs (2) For Nicotine Patch 14mg : Each 20cm2 Nicotine patch contains 35mg nicotine which delivers Nicotine @14mg/24hrs (3) For Nicotine Patch 21mg : Each 30cm2 Nicotine patch contains 52.5mg nicotine which delivers Nicotine @21mg/24hrs			
		4004	Nicotine Patch 14 mg	Required latest product approval from the drug authorities May be considered after furnishing valid/latest product approvals/endorsement from the Drug Authorities	May not be considered
		4003	Nicotine Patch 21 mg	Required latest product approval from the drug authorities May be considered after furnishing valid/latest product approvals/endorsement from the Drug Authorities	May not be considered
		4005	Nicotine Patch 7 mg	Required latest product approval from the drug authorities May be considered after furnishing valid/latest product approvals/endorsement from the Drug Authorities	May not be considered
		140224118	Tab.Morphine sulphate 10mg	Required latest product approval from the drug authorities May be considered after furnishing valid/latest product approvals/endorsement from the Drug Authorities	May not be considered
10	SEEKO BIOTICS	Technical Evaluation Remarks by DGDCA: Product S.No. 3 may be considered/rejected after getting clarification from DME			
	1	1319	Pantaprazole (Enteric Coated) Tablets 40mg		May be considered
	2	1927	Pyridoxine Tablets 10 mg		May be considered
	3	140224067	Tab.Zinc Sulphate 60mg	Pg no.10, provided product approval for 60mg elemental 'Zn' whereas tender requirement is ZnSo4 60mg - clarity is required from DME May be considered after obtaining clarity from DME	NA
	4	1257	Tamoxifen Citrate Tablets 10 mg		May be considered
	5	1962	Tamoxifen Citrate Tablets IP 20 mg		May be considered
11	STRIDE ORGANICS PVT LTD	Technical Evaluation Remarks by DGDCA: The firm may be considered			

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
		1319	Pantaprazole (Enteric Coated) Tablets 40mg		May be considered
12	9M INDIA LIMITED	Technical Evaluation Remarks by DGDCA: The firm may be considered The firm may be considered after submission of clarification regarding Annexure-IV (Certificate from the CA for average Annual turnover of manufacturer in the last three years i.e2020-21,2021-22 and 2022-23 or 2021-22 ,2022-23 and 2023-24)			
		4001	Nicotine 2 mg Gum		May be considered
		4002	Nicotine 4 mg Gum		May be considered
		1319	Pantaprazole (Enteric Coated) Tablets 40mg		May be considered

Note: All the bidders are here by requested to verify the Provisional Technical Evaluation Report and submit their supporting documents on or before 05.00PM on 23.12.2024 to the email id: tenders.apmsidc@gmail.com with Subject : Reply to T No 168-2 (General Medicines) TEC Report